NCT02273661View on ClinicalTrials.gov

Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).

PHASE2CompletedINTERVENTIONAL

Enrollment

174

Participants

Timeline

Start Date

November 19, 2014

Primary Completion Date

June 28, 2019

Study Completion Date

June 28, 2019

Conditions

Allergic Bronchopulmonary Aspergillosis

Interventions

DRUG

Liposomal amphotericin B (Ambisome®)

An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months

DRUG

placebo

An aerosol of isotonic saline x 1/ week will be administered during 6 months

Trial Locations (1)

86000

Chu de Poitiers, Poitiers

All Listed Sponsors

lead

Poitiers University Hospital

OTHER

NCT02273661 - Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded). | Biotech Hunter | Biotech Hunter